Neurological Sciences

, Volume 40, Issue 4, pp 883–885 | Cite as

Multiple sclerosis and oncocytic thyroid carcinoma: fortuitous or drug-related association?

  • Adriana Handra-LucaEmail author
  • Francesco Bacci
Letter to the Editor

To the Editor,


Autoimmune thyroid dysfunction, treatment-related or not, is reported in patients with multiple sclerosis (MS) [1]. We would like to point out another type of thyroid pathology, tumoral, in MS patients, however very rarely encountered. We had recently studied a case of thyroid carcinoma, peculiar by the predominant oncocyte-type component associated to MS.

The patient (man, 28 years) presented with hair loss, diarrhea, thermophobia, tremor, and tachycardia. The medical history revealed allergy (pollen, prawn), and bilateral moderate loss of vision (at the age of 12 years when in North Africa) with probable intermediar uveitis and optic neuritis. Precise data on initial work-up (brain magnetic resonance imaging (MRI), cerebrospinal fluid analysis (CSF), autoimmunity tests, visual evoked potentials) were not available. These complaints may have been a first event of MS. The local team retained a diagnosis of Behcet disease and the patient was treated by oral steroids...



The authors thank Dr. E Maillart as well as Dr. E Sabattini, Dr. B Bisig, Dr. R Scott, Dr. J Smith, Dr. S Singh, Dr. V Vasiliu, and Pr P Gaulard, as well as J Raleche, M Rodrigues, S El Sayeh, V Guzal, C Van Vetteren, I Pluchart, L Jovanov, F Spindler, B Mechekour, N Delva, F Bouchard, F Aurejac, B Mechekour, M De Souza, MC Portenier, and the BIUM and NCA/Avicenne/APHP teams.

Compliance with ethical standards

Ethical statement

The statements noted on the Internet page of the journal (Instructions for Authors) are fullfilled. Enclosed is the pdf of the Internet page.


  1. 1.
    Decallonne B, Bartholomé E, Delvaux V, D'haeseleer M, El Sankari S, Seeldrayers P, Van Wijmeersch B, Daumerie C (2018) Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. Acta Neurol Belg 118(2):153–159CrossRefGoogle Scholar
  2. 2.
    Witte ME, Bø L, Rodenburg RJ, Belien JA, Musters R, Hazes T, Wintjes LT, Smeitink JA, Geurts JJ, De Vries HE, van der Valk P, van Horssen J (2009) Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 219:193–204CrossRefGoogle Scholar
  3. 3.
    Du J, Wang Y, Hunter R, Wei Y, Blumenthal R, Falke C, Khairova R, Zhou R, Yuan P, Machado-Vieira R, McEwen BS, Manji HK (2009) Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A 106:3543–3548CrossRefGoogle Scholar
  4. 4.
    Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, Doglioni C, Ponzoni M, Cicalese MP, Assanelli A, Tommasini A, Brigida I, Dellepiane RM, Martino S, Olek S, Aiuti A, Ciceri F, Roncarolo MG, Bacchetta R (2013) Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immun 146:248–261CrossRefGoogle Scholar
  5. 5.
    Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H (1990) The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:118–127CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Service d’Anatomie pathologique, APHP GHU AvicenneUniversite Paris Nord Sorbonne CiteBobignyFrance
  2. 2.Université Paris Nord Sorbonne Cité, UFR SMBHBobignyFrance
  3. 3.Unit of HematopathologyS. Orsola Malpighi HospitalBolognaItaly

Personalised recommendations